Professor Marja-Riitta Taskinen demonstrates that there are multiple disturbances in TRL metabolism in patients with type 2 diabetes (T2D), resulting in excess generation of remnant particles from both intestine and liver derived TRLs with long residence times in the circulation. As apoC-III is raised in T2D, could it be a promising therapeutic target?
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
